MedTrace Logo

Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers

NCT00357539 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2006-07-27

No results posted yet for this study

Summary

To compare the ocular tolerance, safety and ocular pharmacokinetics of 3 concentrations (0.5% - 1.0% - 1.5%) and the vehicle of T1225.

Conditions

  • Eye Infections, Bacterial

Interventions

DRUG

Azithromycin (T1225)

Sponsors & Collaborators

  • Laboratoires Thea

    lead INDUSTRY

Principal Investigators

  • Claude DUBRAY, Professor · Unité de Pharmacologie Clinique - Clermont-Ferrand (France)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-02-28
Completion
2002-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00357539 on ClinicalTrials.gov